Welcome to LookChem.com Sign In|Join Free
  • or
1,2-Ethanediol, 1-(4-methylphenyl)-, 2-(4-methylbenzenesulfonate), (1S)is a complex organic compound that features a 1,2-ethanediol core with a 1-(4-methylphenyl) group and a 2-(4-methylbenzenesulfonate) group attached. The (1S)designation highlights the specific stereochemistry of the molecule, with the 1-(4-methylphenyl) group oriented in the S configuration. 1,2-Ethanediol, 1-(4-methylphenyl)-, 2-(4-methylbenzenesulfonate),
(1S)is frequently utilized in the realms of organic synthesis and pharmaceutical research, offering a range of potential applications in medicinal chemistry and drug development. Due to its potential toxicity and reactivity, it is crucial to handle and use 1,2-Ethanediol, 1-(4-methylphenyl)-, 2-(4-methylbenzenesulfonate), (1S)- with caution, adhering to all necessary safety protocols and guidelines.

183540-43-4

Post Buying Request

183540-43-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

183540-43-4 Usage

Uses

Used in Organic Synthesis:
1,2-Ethanediol, 1-(4-methylphenyl)-, 2-(4-methylbenzenesulfonate), (1S)is used as a key intermediate in organic synthesis for the creation of various complex organic molecules. Its unique structure allows for versatile chemical reactions, making it a valuable component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1,2-Ethanediol, 1-(4-methylphenyl)-, 2-(4-methylbenzenesulfonate), (1S)is used as a research compound for the development of new drugs. Its specific stereochemistry and functional groups can be leveraged to design and optimize the activity of potential therapeutic agents, contributing to the advancement of medicinal chemistry.
Used in Medicinal Chemistry:
1,2-Ethanediol, 1-(4-methylphenyl)-, 2-(4-methylbenzenesulfonate), (1S)is employed in medicinal chemistry as a building block for the design of novel bioactive molecules. Its structural features can be exploited to create compounds with specific biological activities, targeting various diseases and conditions.
Used in Drug Development:
In the drug development process, 1,2-Ethanediol, 1-(4-methylphenyl)-, 2-(4-methylbenzenesulfonate), (1S)serves as a precursor or a modifying agent to enhance the pharmacological properties of drug candidates. Its incorporation into drug molecules can improve their efficacy, selectivity, and safety profiles, ultimately leading to the development of more effective therapeutics.

Check Digit Verification of cas no

The CAS Registry Mumber 183540-43-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,3,5,4 and 0 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 183540-43:
(8*1)+(7*8)+(6*3)+(5*5)+(4*4)+(3*0)+(2*4)+(1*3)=134
134 % 10 = 4
So 183540-43-4 is a valid CAS Registry Number.

183540-43-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name (S)-(+)-1-(4-Tolyl)-2-(p-tolylsulfonyloxy)ethanol

1.2 Other means of identification

Product number -
Other names (S)-1-(4-Methylphenyl)-1,2-ethanediol 2-tosylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:183540-43-4 SDS

183540-43-4Relevant academic research and scientific papers

Diastereoselective Alkene Hydroesterification Enabling the Synthesis of Chiral Fused Bicyclic Lactones

Shi, Zhanglin,Shen, Chaoren,Dong, Kaiwu

supporting information, p. 18039 - 18042 (2021/11/16)

Palladium-catalysed diastereoselective hydroesterification of alkenes assisted by the coordinative hydroxyl group in the substrate afforded a variety of chiral γ-butyrolactones bearing two stereocenters. Employing the carbonylation-lactonization products as the key intermediates, the route from the alkenes with single chiral center to chiral THF-fused bicyclic γ-lactones containing three stereocenters was developed.

Norepinephrine alkaloids as antiplasmodial agents: Synthesis of syncarpamide and insight into the structure-activity relationships of its analogues as antiplasmodial agents

Aratikatla, Eswar K.,Valkute, Tushar R.,Puri, Sunil K.,Srivastava, Kumkum,Bhattacharya, Asish K.

, p. 1089 - 1105 (2017/08/03)

Syncarpamide 1, a norepinephrine alkaloid isolated from the leaves of Zanthoxylum syncarpum (Rutaceae) exhibited promising antiplasmodial activities against Plasmodium falciparum with reported IC50 values of 2.04 μM (D6 clone), 3.06 μM (W2 clone) and observed by us 3.90 μM (3D7 clone) and 2.56 μM (K1 clone). In continuation of our work on naturally occurring antimalarial compounds, synthesis of syncarpamide 1 and its enantiomer, (R)-2 using Sharpless asymmetric dihydroxylation as a key step has been accomplished. In order to study structure-activity-relationship (SAR) in detail, a library of 55 compounds (3–57), which are analogues/homologues of syncarpamide 1 were synthesized by varying the substituents on the aromatic ring, by changing the stereocentre at the C-7 and/or by varying the acid groups in the ester and/or amide side chain based on the natural product lead molecule and further assayed in vitro against 3D7 and K1 strains of P. falciparum to evaluate their antiplasmodial activities. In order to study the effect of position of functional groups on antiplasmodial activity profile, a regioisomer (S)-58 of syncarpamide 1 was synthesized however, it turned out to be inactive against both the strains. Two compounds, (S)-41 and its enantiomer, (R)-42 having 3,4,5-trimethoxy cinnamoyl groups as side chains showed better antiplasmodial activity with IC50 values of 3.16, 2.28 μM (3D7) and 1.78, 2.07 μM (K1), respectively than the natural product, syncarpamide 1. Three compounds (S)-13, (S)-17, (S)-21 exhibited antiplasmodial activities with IC50 values of 6.39, 6.82, 6.41 μM against 3D7 strain, 4.27, 7.26, 2.71 μM against K1 strain and with CC50 values of 147.72, 153.0, >200 μM respectively. The in vitro antiplasmodial activity data of synthesized library suggests that the electron density and possibility of resonance in both the ester and amide side chains increases the antiplasmodial activity as compared to the parent natural product 1. The natural product syncarpamide 1 and four analogues/homologues out of the synthesized library of 55, (S)-41, (R)-42, (S)-55 and (S)-57 were assayed in vivo assay against chloroquine-resistant P. yoelii (N-67) strain of Plasmodium. However, none of the five molecules, 1, (S)-41, (R)-42, (S)-55 and (S)-57 exhibited any promising in vivo antimalarial activity against P. yoelii (N-67) strain. Compounds 4, 6, 7 and 11 showed high cytotoxicities with CC50 values of 5.87, 5.08, 6.44 and 14.04 μM, respectively. Compound 6 was found to be the most cytotoxic as compared to the standard drug, podophyllotoxin whereas compounds 4 and 7 showed comparable cytotoxicities to podophyllotoxin.

Convenient synthesis of optically active 1,2-diol monosulfonates and terminal epoxides via oxazaborolidine-catalyzed asymmetric borane reduction of α-sulfonyloxy ketones

Cho, Byung Tae,Yang, Weon Ki,Choi, Ok Kyung

, p. 1204 - 1211 (2007/10/03)

A very convenient asymmetric synthesis of 1,2-diol monosulfonates and terminal epoxides with high optical purity via oxazaborolidine-catalyzed asymmetric borane reduction of α-sulfonyloxy ketones using N-ethyl-N-isopropylaniline-borane complex as borane carrier has been developed.

Pyrrolidinyl hydroxamic acid compounds and their production process

-

, (2008/06/13)

A compound of formula (I) STR1 and its pharmaceutically acceptable salt, wherein A is hydrogen or OY, wherein Y is a hydroxy protecting group; Ar is phenyl optionally substituted with one or more substituents selected from halo, hydroxy, C1 -C4 alkyl, C1 -C4 alkoxy, CF3, C1 -C4 alkoxy-C1 -C4 alkyloxy and carboxy-C1 -C4 alkyloxy; X is phenyl, naphthyl, biphenyl, indanyl, benzofuranyl, benzothiophenyl, 1-tetralone-6-yl,C1 -C4 alkylenedioxy, pyridyl, furyl and thienyl these groups optionally being substituted with up to three substituents selected from halo, C1 -C4 alkyl, C1 -C4 alkoxy, hydroxy, NO2, CF3 and SO2 CH3 ; and R is hydrogen, C1 -C4 alkyl or a hydroxy protecting group. These compounds and pharmaceutical compositions containing them are useful as analgesic, anti-inflammatory, diuretic, anesthetic or neuroprotective agents, or an agent for stroke or treatment of functional bowel diseases such as abdominal pain, for the treatment of a mammalian subject, especially a human subject. Further, the present invention provides processes for producing the hydroxamic compounds of formula (I) and their intermediate compounds of the formula. STR2

Aralkylation of guanosine with para-substituted styrene oxides

Barlow, Thomas,Dipple, Anthony

, p. 44 - 53 (2007/10/03)

To probe mechanisms of nucleoside aralkylation, product distributions and product stereochemistries were determined in reactions of optically active p-methyl- and p-bromostyrene oxide with guanosine. The proportion of 7-, N2-, and O6

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 183540-43-4